Aidence vs Alan

Alan has a disclosed valuation of $5.8B, while Aidence's valuation is not publicly available, making a direct size comparison difficult. Alan employs 500-1000 people.

Alan has raised more in total funding at $750M, compared to Aidence's $20M — a gap of $730M. Combined, the two companies have completed 4 known funding rounds.

Alan leads with an Awaira Score of 83/100, while Aidence sits at 45/100. That 38-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Aidence was founded by Jeroen Vendrig in 2016. Alan was founded by Jean-Charles Samuelian in 2016. Visit each company's profile on Awaira for a full founder biography.

Aidence: Aidence develops AI radiology software for lung cancer detection, building CE-marked and FDA-cleared deep learning algorithms that analyse CT scan images to identify and characterise pulmonary nodules requiring clinical follow-up. The Amsterdam company tools assist radiologists in national lung cancer screening programmes and in routine clinical CT reading, providing AI-generated nodule measurements, growth tracking, and malignancy risk scores that reduce reader variability and improve early detection rates.\n\nThe company raised approximately $20 million in venture funding and has deployed its Veye Chest algorithm across multiple European radiology networks and hospital systems participating in national lung cancer screening initiatives. Aidence received CE marking for its software as a medical device and has published clinical validation studies demonstrating performance that is non-inferior to specialist radiologist reads on lung nodule detection tasks.\n\nAidence competes in the AI radiology market alongside Annalise AI, Enlitic, Behold.ai, and Lunit, all of which target chest X-ray and CT reading assistance. The lung cancer screening market has expanded significantly as multiple European countries and the United States have implemented or planned national screening programmes for high-risk smokers, creating a growing workflow automation opportunity for AI lung nodule detection tools. The company was acquired by Coreline Soft, a South Korean medical AI company, as part of a broader consolidation in the AI radiology market. Alan: Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources. The Paris company holds full insurance carrier status in France, Belgium, and Spain, operating as a licensed insurer rather than a distribution intermediary.\n\nThe company raised approximately $220 million including a Series D round from investors including Temasek, Coatue, and Index Ventures, reaching a valuation of approximately $1.4 billion. Alan reports over half a million members across its markets, covering employees at several thousand companies including Stripe, Spendesk, and Vinted, with strong growth in SME employer sales driven by its digital-first enrolment and claims experience. The Alan app provides members with health navigation, symptom checking, and AI-generated health content in addition to insurance card and claims management functionality.\n\nAlan competes in the European digital health insurance market against traditional mutuals including Malakoff Humanis and AG2R La Mondiale, as well as digital health insurers including Henner and Oscar Health in the US context. Its vertical integration as a licensed insurer combined with a technology platform differentiates it from insurtechs that distribute existing insurer products through digital channels, giving Alan full control over the member experience and claims economics. The company is considered one of the most significant French technology companies building in regulated financial services.

Both Aidence and Alan launched in 2016. Same year, but even a few months' head start matters in AI — early movers lock in data, talent, and customer relationships fast.

Aidence has about 1-50 employees; Alan has about 500-1000. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Aidence and Alan compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.